Treatment of endometrial hyperplasia

Phase 4

• Conditions: Condition 1: Other noninflammatory disorders of uterus, except cervix. Condition 2: Endometrial glandular hyperplasia. Condition 3: Endometrial adenomatous hyperplasia.; Other noninflammatory disorders of uterus, except cervix; Endometrial glandular hyperplasia; Endometrial adenomatous hyperplasia

• Registration Number: IRCT201506252624N18
• Lead Sponsor: Vice chancellor for research ,Iran University of Medical Sciences.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 36

Inclusion Criteria

ultrasound which confirms endometrial thickening and simple endometrial hyperplasia without atypia in endometrial sampling.
exclusion criteria: history of intolerance to metformine or mejestrol; using metformine during previous 6 months; history of hepatic or renal disorders; plasma glucose of less than 60 mg/dl or more than 200 mg/dl ; current using of any medication, any gynecologic neoplasia; using any kind of hormones.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Endometrial hyperplasia. Timepoint: 3 months after treatment. Method of measurement: endometrial sampling.